| Value | ₹84.90 Cr |
|---|
BSE filing, NSE: WINDLAS. Summary written from the filing by ALFA Finder's alert engine.
Windlas Biotech Ltd: key numbers
- Share price
- ₹881.10
- Market cap
- ₹1,849 Cr
- Revenue (annual)
- ₹904.1 Cr
- Net profit (annual)
- ₹66.44 Cr
- P/E (TTM)
- 27.8×Sector 48.7×
- Promoter holding
- 63.31%+0.00% QoQ
- FII holding
- 2.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Windlas Biotech Ltd
All →Windlas Biotech Board Meeting Date
Windlas Biotech intimated that its Board meeting is scheduled for 5 November 2026 to consider unaudited standalone results for Q1 FY27. No monetary figure is disclosed in this advance notice.
Windlas Biotech Other Announcement
This quarterly shareholding pattern statement for Windlas Biotech Ltd, covering the period ended September 30, 2026, provides the company's equity ownership breakdown.
Windlas Biotech Management Change
Windlas Biotech appointed Aashish Mehra and Soni Saran Singh as Independent Directors. Vivek Dhariwal resigned as Independent Director and Chairman of the Board.
Windlas Biotech Earnings Call Transcript: Key Takeaways
Windlas Biotech reported record quarterly revenue driven by 29% growth in CDMO vertical. Management focuses on operational excellence and capacity expansion via Plant 6 commercialization.
Windlas Biotech Results Update
Windlas Biotech reported Q1 FY27 revenue of Rs 248 crore, an 18% YoY growth. The release highlights an adjusted EBITDA of Rs 34 crore and PAT of Rs 25 crore.
Windlas Biotech Investor Presentation: Key Takeaways
Windlas Biotech reported Q1FY27 revenue of ₹248 Cr (18% YoY). Adjusted EBITDA and PAT grew 26% and 37% respectively, excluding ESOP costs, driven by CDMO expansion.
Other credit rating announcements
All →Bondada Engineering Credit Rating
CRISIL upgraded credit ratings for five subsidiaries of Bondada Engineering to A/Stable or A-/Stable. The upgrade reflects strong financials and supports the group's lender credibility.
20 Microns Credit Rating
CRISIL reaffirmed 20 Microns' bank loan ratings at A/Stable and A1 on ₹117 crore facilities. Ratings remain unchanged from prior assessment.
Epigral Credit Rating
CRISIL revised Epigral's ratings to CRISIL AA/Stable (long-term) and CRISIL A1+ (short-term) on its bank facilities. The action covers Rs.1,050 Crore of rated bank loan facilities.
Mankind Pharma Credit Rating
CRISIL reaffirmed Mankind Pharma's AA+ rating on Rs.2,500 Crore of NCDs and withdrew ratings on Rs.2,500 Crore NCDs and Rs.1,500 Crore commercial paper. The rating action is dated October 29, 2026.
Lloyds Metals & Energy Credit Rating
Crisil Ratings reaffirmed Lloyds Metals' bank facilities at AA/Stable and A1+, with bank limits enhanced to ₹17,112 crore. It assigned AA/Stable to ₹2,400 crore and ₹1,550 crore of NCDs.
Ram Ratna Wires Credit Rating
CARE Ratings assigned and reaffirmed Ram Ratna Wires' bank facility ratings at CARE A-; Positive / CARE A2+ and revised outlook from Stable to Positive. The long-term bank facilities total Rs.1,046.45 Crore, with several facilities enhanced.